Drug Profile
CC 90005
Alternative Names: CC-90005Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action Protein kinase C theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arthritis; Plaque psoriasis
Most Recent Events
- 23 Aug 2023 Discontinued - Phase-I for Plaque psoriasis in USA (PO)
- 23 Aug 2023 Discontinued - Preclinical for Arthritis in USA (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Arthritis in USA